Press release
United States HER2+ Gastric Cancer Market as Targeted Oncology Gains Global Traction | Top Companies are Ono Pharmaceutical Co. Ltd, Hutchison Medipharma, LintonPharm, Shanghai Henlius Biotech, Genentech USA
HER2+ Gastric Cancer Market
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/her2-gastric-cancer-market?kb
United States: Recent Industry Developments
✅ November 2025: Merck advanced clinical trials combining immunotherapy with HER2-targeted monoclonal antibodies for metastatic gastric cancer.
✅ October 2025: FDA granted priority review to a new antibody-drug conjugate (ADC) designed for HER2-positive gastric tumors.
✅ September 2025: Expansion of precision oncology programs across leading cancer centers accelerated genomic testing for HER2-related mutations.
GCC: Recent Industry Developments
✅ November 2025: UAE launched national initiatives integrating HER2 biomarker testing into early diagnostic pathways for gastric cancer.
✅ October 2025: Oncology departments across Saudi Arabia adopted advanced HER2-targeted biologics into treatment protocols.
✅ September 2025: Qatar strengthened clinical trial collaborations to increase regional participation in HER2-focused immunotherapy research.
MENA: Recent Industry Developments
✅ November 2025: Egypt expanded patient access programs accelerating affordability of HER2-targeted therapies.
✅ October 2025: Morocco introduced HER2 testing across major oncology centers to support early intervention and personalized medicine.
✅ September 2025: Partnerships across the MENA research ecosystem fostered real-world evidence studies for HER2-positive gastric cancer outcomes.
Major Growing Players:
Astrazeneca, Genentech USA, Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd, Hutchison Medipharma, LintonPharm, Shanghai Henlius Biotech, Sanofi, Pfizer, Novartis AG
Latest M&A
✅ HER2+ gastric deals in 2025, but oncology M&A supports pipeline (e.g., Genmab-Merus $8B for bispecifics; Roche-89bio $3.5B including GI cancers). ALX Oncology, Jazz, BeiGene, Zymeworks advance HER2 assets via partnerships; SpringWorks-Merck KGaA adds gastric-relevant inhibitors.
Forecast Projection:
The Global HER2+ Gastric Cancer Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Research Process:
Global HER2+ Gastric Cancer Market report is built on solid intelligence - powered by both primary and secondary research. Our analysts have deep-dived into every factor that can influence your business roadmap, including government regulations, competitive landscape, tech innovations, historical market behavior, upcoming breakthroughs, adjacent industry trends, market volatility, growth prospects, and potential risks.
Government Regulations
✅ FDA CAP guideline standardizes HER2 testing (IHC/ISH) for GEA decisions, requiring multidisciplinary care and performance status checks before trastuzumab. MHRA (UK) approved trastuzumab deruxtecan (Enhertu) extension for metastatic HER2+ solid tumors (Apr 2025). EU/US emphasize biomarker-driven therapy; Project Orbis accelerates approvals
Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports): https://www.datamintelligence.com/buy-now-page?report=her2-gastric-cancer-market?kb
Key Segments:
By Therapy; (Immunotherapy, Chemotherapy, Radiation Therapy, Targeted Therapy)
By Stage: (Stage I, Stage II, Stage III, Stage IV)
By End User: (Hospitals, Speciality Clinics, Ambulatory Surgical Centers)
Regional Analysis for Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Benefits of the Report:
Chapter 1: sets the stage by defining the full scope of the report and delivering an executive summary of key market segments across regions, product types, and applications. It provides a comprehensive snapshot of current market sizes and reveals future growth potential, offering a clear vision of how the market will evolve in the short, mid, and long term.
Chapter 2: uncovers critical insights and highlights the most impactful emerging trends shaping the HER2+ Gastric Cancer market's future - essential knowledge for investors and strategists looking to stay ahead.
Chapter 3: dives deep into the competitive landscape, delivering an in-depth analysis of HER2+ Gastric Cancer manufacturers. It covers market share dynamics, strategic developments, and the latest mergers and acquisitions that are redefining the industry.
Chapter 4: profiles the market's leading players, offering detailed views of their revenue streams, profit margins, product portfolios, and recent innovations - arming you with the intel to benchmark and strategize effectively.
Chapters 5 & 6: break down revenue performance by region and country, providing a quantitative analysis that spotlights growth hotspots, development prospects, and the unique opportunities each market offers across the globe.
Chapter 7: explores market segmentation by type, revealing the size and untapped potential of each segment - guiding you toward lucrative "blue ocean" opportunities that competitors may have overlooked.
Chapter 8: analyzes the market by application, evaluating downstream sectors with the highest growth potential and identifying promising areas for expansion and investment.
Chapter 9: maps the entire industry supply chain, tracing upstream suppliers to downstream distributors, giving you full visibility into critical business linkages and value drivers.
Chapter 10: wraps up with a powerful summary of the report's key findings and strategic takeaways, delivering the must-know insights every industry stakeholder needs to make confident, forward-looking decisions.
Get Customization in the report as per your requirements: https://datamintelligence.com/customize/her2-gastric-cancer-market?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States HER2+ Gastric Cancer Market as Targeted Oncology Gains Global Traction | Top Companies are Ono Pharmaceutical Co. Ltd, Hutchison Medipharma, LintonPharm, Shanghai Henlius Biotech, Genentech USA here
News-ID: 4298253 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Medical Transcription Service Market to Reach US$ 65.70 Billion by 2031 at 5.3% …
Medical Transcription Service Market reached US$ 43.46 billion in 2023 and is expected to reach US$ 65.70 billion by 2031, growing at a CAGR of 5.3% during the forecast period 2024-2031.
Medical transcription (MT) involves the accurate conversion of diverse healthcare audio recordings into structured written documentation, including clinical reports, consultation notes, discharge summaries, psychiatric evaluations, referrals, interviews, and patient medical histories dictated by healthcare professionals. These transcription outputs form a…
Urban Air Mobility Market Set for Explosive Growth to USD 54.03 Billion by 2032, …
The Global Urban Air Mobility Market reached USD 4.84 billion in 2024 and is expected to reach USD 54.03 billion by 2032, growing with a robust CAGR of 35.20% during the forecast period 2025-2032.
Market growth is driven by rapid urbanization, surging demand for efficient short-distance transportation, and advancements in electric vertical takeoff and landing (eVTOL) aircraft. Supportive government regulations, substantial investments from aerospace giants like Joby Aviation and Lilium, expanding…
Stair Lifts Market to Reach USD 3.24 Billion by 2032 at 8.6% CAGR | North Americ …
Stair Lifts Market reached USD 1.36 billion in 2024 and is expected to reach USD 3.24 billion by 2032, growing at a CAGR of 8.6% during the forecast period 2025-2032.
The stair lifts market is being driven by the rapidly ageing global population, increasing prevalence of mobility-related disabilities, and a growing preference for ageing-in-place solutions that enhance independence and quality of life for seniors and individuals with physical limitations. Stair lifts…
United States Injection Molding Market Insights 2033 | Growth in Key Industries, …
Injection Molding Market reached US$ 295 billion in 2024 and is expected to reach US$ 451.83 billion by 2033, growing at a CAGR of 5% during the forecast period 2025-2033
Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/injection-molding-market?kb
Injection Molding Market: Trends, Services, and Innovations Shaping the Industry
The Injection Molding Market continues to evolve rapidly, driven by advancements in materials, technologies, and customized manufacturing solutions.…
More Releases for HER2
HER2-Positive Breast Cancer (HER2+ BC) Clinical Market to Reach USD 21.46 Billio …
Sub-Headline: The global HER2-Positive Breast Cancer Clinical Market is expected to rise from USD 13.82 billion in 2023 to USD 21.46 billion by 2030, registering a CAGR of 6.5%, driven by rapid uptake of antibody-drug conjugates (ADCs), dual-targeted therapies, and AI-enabled precision oncology diagnostics.
Introduction
The HER2-Positive Breast Cancer (HER2+ BC) Clinical Market is undergoing a major transformation fueled by next-generation targeted therapies, breakthrough ADCs, biosimilar expansion, and genomic testing advancements. HER2+…
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
